- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC | Clinical
Key Takeaways of the Survival Outcomes From the LEAP-002 Trial for HCC
November 23, 2022
Richard S. Finn, MD, discusses key takeaways of the LEAP-002 trial of frontline pembrolizumab and lenvatinib for hepatocellular carcinoma.
Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCC
November 09, 2022
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
FDA Grants Orphan Drug Designation to OTX-2002 in HCC
November 02, 2022
OTX-2002 has received an orphan drug designation by the FDA for patients with hepatocellular carcinoma. The agent will further be evaluated in the phase 1/2 MYCHELANGELO trial.
An Abundance of Therapies for Early- and Late-Line HCC
November 02, 2022
Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.
Health Derailed in Houston After Authorities Confirm Liver Cancer Cluster
October 31, 2022
Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.
Background of the LEAP-002 Trial Evaluating Lenvatinib Monotherapy in uHCC
October 31, 2022
Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.
Interpreting Results From New and Previous Trials of Lenvatinib in HCC
October 26, 2022
During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular Carcinoma
October 26, 2022
Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
FDA Approves Durvalumab Plus Tremelimumab for Unresectable HCC
October 24, 2022
Findings from the phase 3 HIMALAYA trial have led the FDA to grant approval to the combination of tremelimumab and durvalumab for the treatment of patients with unresectable hepatocellular carcinoma.
FDA Grants Fast Track Designation to TT-101 for Advanced HCC
October 19, 2022
TTI-101, an oral, small molecule, STAT3 inhibitor, has been granted fast track designation by the FDA for patients with hepatocellular carcinoma.